Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
Defending champion South Carolina to open season in Las Vegas against Michigan
COLUMBIA, S.C. (AP) — Defending national champion South Carolina has another splashy opening planned2024-05-21Five UFO abduction cases that could FINALLY be solved
Roughly 100 alien abduction cases spanning over the past 30 years are set to be investigated by scie2024-05-21Haiti violence: Haitians scramble to survive as gang violence chokes capital
PORT-AU-PRINCE, Haiti (AP) — As the sun sets, a burly man bellows into a megaphone while a curious c2024-05-21Taylor Swift sends secret message to Travis Kelce in So High School's lyric video
Taylor Swift sent a sweet musical message to her boyfriend, Travis Kelce, in the lyric video for her2024-05-21- A small group of NFL rookies from the 2024 class, including Caleb Williams and Drake Maye, sat down2024-05-21
Ingenious ways to escape boring conversations without appearing rude
Perfecting the art of conversation is a powerful tool - but so too, it seems, is learning how to esc2024-05-21
atest comment